Ian Bouligny, MD
Department of Leukemia, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas
Education & Training
Degree-Granting Education
| 2017 | LSU Health Shreveport School of Medicine, Shreveport, LA, US, Medicine, MD |
| 2013 | Louisiana State University, Baton Rouge, LA, US, Biological Sciences, BS |
Postgraduate Training
| 2023-2024 | Fellowship, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2020-2023 | Fellowship, VCU Massey Cancer Center, Richmond, VA |
| 2017-2020 | Residency, Internal Medicine, Wake Forest Baptist Health, Winston-Salem, North Carolina |
Experience & Service
Administrative Appointments/Responsibilities
Project ERIS Team Leader, Department of Hematology & Oncology, VCU, Richmond, VA, 2022 - 2023
Leukemia Clinical Research Team Leaders, Department of Leukemia, VCU, Richmond, VA, 2021 - 2023
Resident Research Committee Leaders, Department of Hematology & Oncology, Wake Forest Hematology & Oncology, Winston-Salem, North Carolina, 2019 - 2020
Internal Medicine Residency Accommodations Partnership, Department of Internal Medicine, Wake Forest, Winston-Salem, North Carolina, 2018 - 2020
Accommodations Partnership, Wake Forest School of Medicine, Winston-Salem, North Carolina, 2018 - 2020
Vice President of the Deaf and Hard-of-Hearing Club, LSU Baton Rouge, Baton Rouge, LA, 2013 - 2013
Other Appointments/Responsibilities
Project Eris Team Leader, Leukemia, VCU Hematology & Oncology, Richmond, VA, 2023 - 2023
Leukemia Clinical Research Team Leader, VCU Hematology & Oncology, Richmond, VA, 2021 - 2023
Resident Research Committee Leader, Wake Forest Hematology & Oncology, Winston-Salem, NC, 2019 - 2020
Accommodations Partnership, Wake Forest School of Medicine, Winston-Salem, NC, 2018 - 2020
Residency Accommodations Partnership, Wake Forest Internal Medicine, Winston-Salem, NC, 2018 - 2020
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Bouligny IM, DiNardo CD. Oral decitabine-cedazuridine in acute myeloid leukaemia. Br J Haematol 205(5):1674-1676, 2024. e-Pub 2024. PMID: 39313925.
- Murray GF, Bouligny IM, Ho T, Gor J, Zacholski K, Wages NA, Grant S, Maher KR. Clonal Evolution in 207 Cases of Refractory or Relapsed Acute Myeloid Leukemia. Eur J Haematol 114(1):98-104, 2024. e-Pub 2024. PMID: 39315590.
- Bouligny IM, Murray G, Doyel M, Patel T, Boron J, Tran V, Gor J, Hang Y, Alnimer Y, Ho T, Zacholski K, Venn C, Wages NA, Grant S, Maher KR. Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia. Med Oncol 41(3):80, 2024. e-Pub 2024. PMID: 38396145.
- Bouligny IM, Murray G, Ho T, Doyel M, Patel T, Boron J, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Wages NA, Grant S, Maher KR. Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia. Res Sq, 2023. e-Pub 2023. PMID: 37398154.
- Bouligny IM, Murray G, Doyel M, Patel T, Boron J, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Wages NA, Grant S, Maher KR. Venetoclax with decitabine or azacitidine in the first-line treatment of acute myeloid leukemia. EJHaem 4(2):381-392, 2023. e-Pub 2023. PMID: 37206255.
- Bouligny IM, Maher KR, Grant S. Augmenting Venetoclax Activity Through Signal Transduction in AML. J Cell Signal 4(1):1-12, 2023. e-Pub 2023. PMID: 36911757.
- Bouligny IM, Mehta V, Isom S, Ellis LR, Bhave RR, Howard DS, Lyerly S, Manuel M, Dralle S, Powell BL, Pardee TS. Efficacy of 10-day decitabine in acute myeloid leukemia. Leuk Res 103:106524, 2021. e-Pub 2021. PMID: 33640708.
Other Articles
- Bouligny IM, Maher KR, Grant S Secondary-Type Mutations in Acute Myeloid Leukemia: Updates from ELN 2022. Cancers (Basel) 15(13), 2023. PMID: 37444402.
- Bouligny IM, Maher KR, Grant S Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives. Blood Rev 57:100996, 2023. PMID: 35989139.
- Maher KR, Bouligny IM, Yeager AM Prevention and management of infections after exposure to ionizing radiation. J Radiol Prot 41(4), 2021. PMID: 34265748.
Abstracts
- Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. Back in JAK - Real-World Analysis of JAKmut AML. Blood 140(1):11812–11813, 2022. e-Pub 2022.
- Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. Healthcare Disparities Among African Americans Are Pervasive in the Treatment of AML. Blood 140(1):5281–5282, 2022. e-Pub 2022.
- Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. Outcomes of FLAG-IDA Versus MEC in Relapsed or Refractory AML. Blood 140(Supplement 1):11742–11743, 2022. e-Pub 2022.
- Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. Real-World Safety and Efficacy of Gemtuzumab Ozogamicin in Relapsed or Refractory AML. Blood 140(1):11744, 2022. e-Pub 2022.
- Bouligny IM, Murray G, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Maher K. Efficacy of Hypomethylating Agents with Venetoclax in TP53mut AML. Blood 140(1):11842–11843, 2022. e-Pub 2022.
Letters to the Editor
- Bouligny IM, Montalban-Bravo G, Sasaki K, Daver N, Jabbour E, Alvarado Y, DiNardo CD, Ravandi F, Borthakur G, Pemmaraju N, Kadia T, Masarova L, Takahashi K, Andreeff M, Bazinet A, Yang H, Kanagal R, Pierce S, Meyer M, Huang X, Garcia-Manero G. A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms. Leukemia 39: 524-528, 2025.
- Bouligny IM, Murray G, Ho T, Doyel M, Patel T, Boron J, Tran V, Gor J, Hang Y, Alnimer Y, Zacholski K, Venn C, Wages NA, Grant S, Maher KR. Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia. Leuk Res 134: 107370, 2023.
Patient Reviews
CV information above last modified March 28, 2025